Aging & Elder Health Week
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Aging & Elder Health Week
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Allon Therapeutics, Inc.
Glaucoma compounds show potential to treat eye disease
April 10th, 2005
Two proprietary compounds of Allon Therapeutics, Inc., (NPC) have the potential to become new treatments for diseases of the optic nerve and retina - including glaucoma, the second most common cause of blindness in the United States - according to results of a preclinical study published in the March issue of Investigative Ophthalmology & Visual Science. The two compounds are AL-108, Allon's lead product candidate now being evaluated in human clinical trials as a treatment for Alzheimer disease, and AL-209, one of Allon's preclinical-stage product candidates. Several diseases of the optic nerve and retina, including glaucoma, involve the...
Source: Aging & Elder Health Week (2005-04-10)
|
